Brief: Revive Therapeutics Announces Submission Of Irb Approval For Phase 3 Clinical Trial Protocol For Bucillamine In Covid-19
26/08/2020 14:28
Aug 26 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS ANNOUNCES SUBMISSION OF IRB APPROVAL
FOR
PHASE 3 CLINICAL TRIAL PROTOCOL FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - EXPECTS TO HAVE PATIENTS
ENROLLED IN
SEPTEMBER 2020 FOR PHASE 3 CLINICAL TRIAL PROTOCOL FOR
BUCILLAMINE IN COVID-19
* REVIVE - EXPLORING FDA EXPANDED ACCESS PROGRAM, THAT CAN
PROVIDE
ACCESS TO BUCILLAMINE FOR THOSE WHO MEET PROTOCOL CRITERIA OF
COVID-19 STUDY
Source text for Eikon: ID:nGNX3QhvVf
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure